Translational studies in nonhuman primates and human volunteers support the phase 2 program for ravagalimab in moderately to severely active ulcerative colitis

Stefan Schreiber  1     Stephen H. Clarke  2     Bradford L. McRae  2     Robert G. Caldwell  3     Ahmed Nader  3     Gabriela Alperovich  4     Andreas Lazar  5    
1 Universit├Ąt Kiel UKSH,Kiel,Germany
2 AbbVie Bioresearch Center,Worcester,United States
3 AbbVie Inc.,North Chicago,United States
4 Abbvie,Madrid,Spain
5 AbbVie Deutschland GmbH & Co KG Abt. Immunologie,Ludwigshafen,Germany

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing